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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.008Human-speciﬁc HIV-1 and hepatitis co-infections signiﬁcantly affect patient management and call for
new therapeutic options. Small xenotransplantation models with human hepatocytes and hema-
tolymphoid tissue should facilitate antiviral/antiretroviral drug trials. However, experience with mouse
strains tested for dual reconstitution is limited, with technical difﬁculties such as risky manipulations
with newborns and high mortality rates due to metabolic abnormalities. The best animal strains for
hepatocyte transplantation are not optimal for human hematopoietic stem cell (HSC) engraftment, and
vice versa. We evaluated a new strain of highly immunodeﬁcient nonobese diabetic/Shi-scid (severe
combined immunodeﬁciency)/IL-2Rgc
null (NOG) mice that carry two copies of the mouse albumin
promoter-driven urokinase-type plasminogen activator transgene for dual reconstitution with human
liver and immune cells. Three approaches for dual reconstitution were evaluated: i) freshly isolated fetal
hepatoblasts were injected intrasplenically, followed by transplantation of cryopreserved HSCs obtained
from the same tissue samples 1 month later after treosulfan conditioning; ii) treosulfan conditioning is
followed by intrasplenic simultaneous transplantation of fetal hepatoblasts and HSCs; and iii) trans-
plantation of mature hepatocytes is followed by mismatched HSCs. The long-term dual reconstitution
was achieved on urokinase-type plasminogen activatoreNOG mice with mature hepatocytes (not fetal
hepatoblasts) and HSCs. Even major histocompatibility complex mismatched transplantation was sus-
tained without any evidence of hepatocyte rejection by the human immune system. (Am J Pathol 2014,
184: 101e109; http://dx.doi.org/10.1016/j.ajpath.2013.09.008)Supported by an Institutional Development Award (IDeA) from the
National Institute of General Medical Sciences of the National Institutes of
Health grant P20GM103480.In Europe, Australia, and North America at least 25% of
HIV-infected persons have a concomitant hepatitis C virus
(HCV) infection, and 5% to 10% are co-infected with
chronic hepatitis B virus (HBV).1 Although the incidence of
monoinfections (HIV, HBV, and HCV) is declining because
of prophylaxis, vaccination, and newly available treatments,
co-infections of HIV with HBV/HCV are still problematic,
and the medical care of these co-infected patients remains a
difﬁcult task.1,2 These human-speciﬁc co-infections require
a small animal model to study double infections, such as
HIV/HCV or HIV/HBV, and to test new antiviral/antire-
troviral therapeutics.
A search is ongoing for the best strain of mice for dual
reconstitution and available tissue sources. Among multiplestigative Pathology.
.mouse models for human hepatocyte transplantation, the
most robust and effective for mouse liver cell depletion and
human hepatocytes engraftment are tyrosine catabolic
enzyme fumarylacetoacetate hydrolase (Fah) mutants3 and
transgenic mice with a tandem array of murine urokinase
genes under the control of the albumin promoter (Alb-uPA)
on a CB-17-scid-bg background.4 The advantages (up to
99% of human hepatocyte reconstitution) and the disad-
vantages (colony maintenance, limited time window for
transplantation, and mouse health problems) of these mouse
Gutti et almodels for liver repopulation with human hepatocytes have
been extensively discussed.5e8 Several models for human
hematopoietic stem cell (HSC) transplantation are based on
the nonobese diabetic (NOD) and BALB/c background
mouse strains, known as NOG (NOD/Shi-scid/IL-2Rgc
null),9
NSG (NOD/scid/gC
//SzJ),10 and double knockout for
Rag2þIL-2Rgc.11,12 A successful co-transplantation of fetal
human liver cells and HSCs has been reported in double
knockout BALB/c mice with the transgenic expression of
the FK506 binding proteinecaspase 8 fusion gene driven by
the albumin enhancer/promoter.13 Despite partial success,
the manipulation of newborn animals and the use of fetal
tissues create technical and ethical problems.
An important issue for any model that is based on human
tissue is the source and type of hepatocytes that can be used
for transplantation, which must be syngeneic (matched) with
HSCs for immune system reconstruction in experimental
animals. The fetal liver provides both types of cells for
transplantation. A possible choice is fetal liver cells with a
progenitor phenotype that expresses epithelial cell adhesion
molecule (CD326).14 The adult hepatocytes can be trans-
planted with high efﬁciency and can be sustained long
enough6; however, the matched sources of HSCs are
limited. These cells must be isolated from the same donor
bone marrow or peripheral blood. Thus, no existing model
is ideal for dual reconstitution.
Here, we investigated the utility of a new urokinase-type
plasminogen activator (uPA)-NOG strain15 of mice for dual
reconstitution and compared different sources of human
cells for transplantation. A homozygous line of uPA-NOG
mice carries two copies of the transgene array that stably
reinforces transgene expression. Perinatal bleeding, embry-
onic or neonatal lethality, and severe tissue pathology did
not occur in homozygous uPA-NOG mice compared with
Alb-uPA/scid mice. The alanine aminotransferase (ALT)
levels were persistently elevated along with evidence of
modest hepatic injury by 6 weeks of age in the uPA-NOG
homozygotes. Compared with Alb-uPA/scid transgenic
mice, which have an age-dependent decrease in uPA
expression caused by deletion of the integrated transgene, a
relatively low frequency of physical loss of the transgene is
observed from uPA-NOG mice. The persistence of the he-
patic injury marker should facilitate human hepatocyte
engraftment and expansion throughout the life of the
mouse.15 This property of uPA-NOG strain allows for the
manipulation of adult animals and expands the window for
human cell transplantation. The engraftment of HSCs also
requires the creation of a niche in mouse bone marrow for
human cells. The widely used total body irradiation in-
creases the risks of severe bacteremia and body weight loss.
In this study, we used non-myeloablative conditioning with
treosulfan as a safe and well-tolerated alternative to total
body irradiation for HSC transplantation.16e20 Human he-
patocyte engraftment at the 3% to 5% level is adequate to
perform important studies on intrahepatic pathogens, such
as those that cause malaria and hepatitis B. Successful HCV102infection was achieved with >10% of hepatocytes being of
human origin. Efﬁcient hematolymphoid repopulation in
combination with partial liver repopulation is sufﬁcient to
study HIV co-infection, and uPA-NOG mice offer this
possibility.
Materials and Methods
Animals
The uPA-NOG mice were provided by Central Institute for
Experimental Animals (Kanagawa, Japan)15 and were bred
in the animal breeding facility at the University of
Nebraska Medical Center. All animal procedures were
approved by the University of Nebraska Medical Center
Animal Care and Use Committee and were within the
guidelines for humane care of laboratory animals. Female
hemizygotes (nZ 5) and male homozygotes (nZ 3) were
obtained, and 158 pups were generated by breeding. The
zygosity was determined by the degree of liver damage
observed by the serum levels of ALT. Serum ALT levels
from 6-week-old males were determined by VetScan VS2
(Abaxis, Union City, CA), and males with elevated ALT
were selected for transplantation. Females were used for
the next breeding, and we found that homozygous females
were able to produce one litter before 4 to 5 months of age
when these mice showed phenotypically high ALT levels.
NSG mice (The Jackson Laboratory, Bar Harbor, ME;
stock no. 005557) were obtained from our breeding col-
ony, which was established in 2005.
Human Cells
HSCs and hepatoblasts were isolated from fetal tissue
(Fhbs). Tissues were provided by the University of Wash-
ington, Laboratory of Developmental Biology, supported
by the National Institutes of Health Award 5R24HD000836
and the Eunice Kennedy Shriver National Institute of Child
Health and Human Development (90e117 days of gesta-
tion). The tissues arrived 48 hours after collection and were
mechanically disrupted, and the resulting fragments were
treated with collagenase, hyaluronidase, and DNase at
37C. The resulting suspensions were washed with medium
that contained fetal calf serum, were centrifuged at 50  g,
and processed as described.21 Viability (as evaluated by
trypan blue exclusion) always exceeded 80% in the trans-
planted samples. The fractions contained 1% to 6% asialo
glycoprotein receptor-positive hepatocytes as determined
by staining with anti-asialo glycoprotein receptor
1ephycoerythrin (PE) antibodies (Santa Cruz Biotech-
nology Inc., Santa Cruz, CA).22 Collected after low-speed
centrifugation, the supernatant ﬂuid was used to isolate
HSCs. CD34þ HSCs were isolated by using the CD34
MicroBead Kit (Miltenyi Biotec, Auburn, CA), and the
purity of the isolated cells evaluated by ﬂuorescence-
activated cell sorting (FACS) was >90%. CD34þ cellsajp.amjpathol.org - The American Journal of Pathology
Figure 1 Schematic outlines of the experimental approaches tested in
uPA-NOG mice. A: Freshly isolated fetal liver cells were infused ispl. The
presence of hu-Alb in peripheral blood was conﬁrmed 4 weeks later, and
cryopreserved HSCs were administered i.v. after 3 days of chemotherapeutic
conditioning with treosulfan. Fetal liver cells did not survive, and the mouse
remained mono-reconstituted. The pink color of the spleen represents
hematolymphoid reconstitution (Approach I). B: Isolated liver cells and
HSCs were infused in a 1:1 ratio ispl., lower levels of hu-Alb were observed,
and the mouse remained mono-repopulated (Approach II). C: Cry-
opreserved adult hepatocytes were ﬁrst transplanted and then mismatched
HSCs were derived from the fetal liver. Animals were dual reconstituted with
human hematolymphoid cells and hepatocytes (Approach III).
Dual Reconstituted Micewere frozen for future transplantation. Adult hepatocytes
were obtained from 6-month-old donors. The hepatocytes
were cryopreserved and were 80% viable and 40% attach-
ment efﬁcient at the time of transplantation.
Transplantation of Hepatocytes and HSCs
Samples of freshly isolated Fhbs were injected intraspleni-
cally (ispl.) at 2  106 cells/mouse.23 Recipient mice were
anesthetized with a xylozine and ketamine combination
diluted in distilled water. The left sides of the mice were
disinfected with a betadine solution, and a 1.5-cm cut was
made 5 mm below the lower edge of the rib cage to enter the
peritoneal cavity. The spleen was located and protracted
slightly with the blunt-ended forceps, and the lower pole
was ligated with a suture. The injection needle of the 1-mL
syringe was inserted through the ligation into the spleen,
and 100 mL of the cell suspension was injected slowly into
the spleen. The needle was retracted, and the ligation was
tightened. The spleen was pushed back into the body cavity,
and the peritoneum and skin were closed with 3-0 absorb-
able sutures. The conditioning of the animals for HSC
transplantation was done with a non-myeloablative regimen
of treosulfan (medac GmbH, Hamburg, Germany), intra-
peritoneally injected for 3 days at a dose of 1.5 g/kg/day.
CD34þ cells were intravenously (i.v.) transplanted into mice
at 0.5 to 1  106 cells/mouse in 100 mL of PBS via the tail
vein with the use of a 28G1/2-gauge needle or with hep-
atoblasts in 1:1 ratio by intrasplenic injection. Figure 1,
AeC, shows the schematic representation of experimental
approaches. Five sets of experiments were conducted, and
six donor samples and 30 animals were used for approach I.
The engraftment was evaluated by the human Alb (hu-Alb)
concentration in peripheral blood samples at 4 weeks
after surgery. For the second approach of intrasplenic co-
transplantation of hepatoblasts and HSCs two samples of
donor tissues and 10 animals were used. The third approach
included transplantation of cryopreserved hepatocytes after
transplantation of cryopreserved mismatched HSCs (nZ 8).
hu-Alb Level Evaluation
The hu-Alb levels in mice that received a transplant were
measured every 4 to 5 weeks by using a Human Albumin
ELISA (enzyme-linked immunosorbent assay) Quantitation
kit (Bethyl Laboratories, Inc., Montgomery, TX). Western
blot analysis conﬁrmed the presence of hu-Alb. Animal
plasma samples were diluted 1:3 in PBS and were mixed
with SDS sample buffer with 5% b-mercaptoethanol
(Sigma-Aldrich, St. Louis, MO) in 1:1 ratio. The proteins
were subjected to SDS-PAGE and were transferred to
Hybond-ECL membranes (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ). The membranes were incubated
overnight with mouse monoclonal anti-human serum albu-
min antibody diluted 1:2000 (Abcam Inc., Cambridge,
MA; ab no. 10241) and goat anti-mouse IgGehorseradishThe American Journal of Pathology - ajp.amjpathol.orgperoxidase conjugate (Sc-2005; Santa Cruz Biotechnology
Inc.) secondary diluted 1:10,000 for 30 minutes. The im-
munoblots were developed with the ECL Western Detection
System and Hyperﬁlm ECL (GE Healthcare Bio-Sciences
Corp.).
Flow Cytometry
Peripheral blood samples were collected from the facial vein
in EDTA-coated tubes. Six-color FACS analyses of whole
blood samples were performed to monitor changes in the
human cell populations. In brief, 100-mL aliquots of whole
blood were incubated with respective antibodies for 30 mi-
nutes at 4C. The red blood cells were ﬁrst lyzed with FACS
Lysing Solution (Becton Dickinson, San Jose, CA) and then
washed twice with PBS that contained 2% fetal bovine
serum. Blood leukocytes were tested for human pan-CD45,
CD3, CD4, CD8, CD14, and CD19 markers by multicolor
panel. Antibodies and isotype controls were obtained from
BD Pharmingen (San Diego, CA), and the staining was
analyzed with a FACS DIVA (BD Immunocytometry103
Figure 2 Liver damage levels and the kinetics of human albumin
plasma concentration in uPA-NOG mice after fetal or adult hepatocyte
transplantation. A: The ALT levels in 6- to 8-week-old mice for all three
schemes were comparable. B and C: Scheme I, whereby Fhbs were
transplanted ﬁrst after syngeneic cryopreserved HSC intravenous injec-
tion. B: Western blot analysis detected human albumin in 5 mL of mouse
plasma diluted 1:3. Lanes 2 to 9 represent individual mice at 10 weeks
after Fhb transplantation. Lane 10 represents hu-Alb detected in 1 mL of
pooled (AB) sera diluted 100 times. C: ELISA-based detection of hu-Alb
in mouse plasma. D: Scheme II, whereby treosulfan-conditioned animals
received ispl. a transplant with a combination of two types of cells: Fhbs
and HSCs. Fhbs did not sustain in uPA-NOG mouse liver regardless of
combination with HSCs or adenovirus expressing human hepatocyte
growth factor administration. E: Scheme III, whereby adult hepatocytes
were transplanted ﬁrst after treosulfan-conditioning and mismatched
HSC intravenous injection. Adult hepatocytes were sustained in the
mouse liver in the presence of mismatched hematopoiesis and lymphoid/
macrophage repopulation. Open symbols represent mice with reduced
hu-Alb concentration at the end of observation. Individual measure-
ments and medians are shown.
Gutti et alSystems, Mountain View, CA). The results were expressed
as percentages of the total number of gated lymphocytes. The
gating strategy was human CD450CD30CD4/CD8,
CD450CD19, and CD450CD14.
Immunohistochemistry
Tissues were ﬁxed with 4% paraformaldehyde overnight at
4C and then embedded in parafﬁn. Five-micron sections
were cut from the parafﬁn blocks, mounted on glass slides,
and subjected to immunohistochemical staining with
mouse monoclonal antibodies for HLA (human leukocyte
antigen)-DQ/DP/DR (clone CR3/43, 1:100 dilution), CD45
(1:200 dilution), CD68 (1:100 dilution), and cytokeratin 18
(clone DC 10, 1:33 dilution) from Dako (Carpinteria, CA),
and a-smooth muscle actin (1:50 dilution) antibodies from
Abcam Inc., the M30CytoDEATH (1:10 dilution) antibody
was purchased from Roche Applied Science (Indianapolis,
IN), the rabbit monoclonal antibody for CD8 (1:100 dilu-
tion) antibody was purchased from Abcam Inc,, and the
trichrome stain was purchased from ScyTek Laboratories,
Inc. (Logan, UT). Polymer-based horseradish peroxidasee
conjugated anti-mouse Dako EnVision systems were used
as secondary detection reagents and were developed with
3,30-diaminobenzidine. All parafﬁn-embedded sections
were counterstained with Mayer’s hematoxylin. For
immunoﬂuorescent staining, secondary anti-mouse and
anti-rabbit Alexa Fluor 488 and Alexa Fluor 594 and blue-
ﬂuorescent DAPI nucleic acid stain were used (Invitrogen,
Eugene, OR). Bright ﬁeld and immunoﬂuorescent images
were obtained with a Nikon Eclipse E800 (Nikon In-
struments, Melville, NY) with the use of NIS-Elements F
version 3.0 software (Nikon Instruments). Immunoﬂuores-
cent images were incorporated into a spectral unmixing
algorithm (Nuance version 2.10; Advanced Molecular
Vision, Lincolnshire, UK) that quantitatively separated the
gray-scale images that represent each spectral component.
Results
Outcomes for Liver Cell Transplantation in uPA-NOG
Mice Depend on the Experimental Approach
Three experimental approaches for the construction of mice
combining human immune and liver cells are presented in
Figure 1, AeC. Animals for human liver cell transplantation
were selected on the basis of elevated ALT activity in the
peripheral blood at 6 to 8 weeks of age (Figure 2A). For the
ﬁrst approach, we transplanted Fhbs via intrasplenic infu-
sion (2e3  106 cells/mouse). Then, the animals were
conditioned with treosulfan, and the cryopreserved HSCs
(106 cells/mouse isolated from the same donor tissue sam-
ples) were injected i.v. The liver repopulation by human
Fhbs was monitored by the hu-Alb ELISA up to 30 weeks
after surgery. At 4 weeks after Fhb transplantation, hu-Alb
levels >1 mg/mL were detected in 14 animals (median,104 ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Liver pathomorphology in two representative dual recon-
stituted uPA-NOG mice. A and B: Clusters of human hepatocytes were
immunostained with human-speciﬁc cytokeratine-18. C and D: Magniﬁed
view of selected regions of human hepatocytes is shown. E and F: Scat-
tering human HLA-DR-positive lymphocytes, macrophages, and Kupffer
cells in close proximity in tissue sections of panels A and B. Signiﬁcant
brown-stained areas are occupied by activated human macrophages/his-
tiocytes (F). G and H: The regions with activated human macrophages were
also positively immunostained for a-smooth muscle actin. I: Immunoﬂu-
orescent staining of human CD8þ cells (red) and mismatched hepatocytes
by cytokeratine-18 (green). J: The accumulation of human CD8þ lympho-
cytes (red) was not observed around mismatched human hepatocytes and
was often found in areas with a signiﬁcant number of human CD68þ
macrophages. Represented are mouse 1561 (A, C, E, and G) and mouse
1563 (B, D, F, H, I, and J) with 171.1 mg/mL and 280 mg/mL hu-Alb blood
levels at the end point of observation, respectively. Original magniﬁcation:
40 (A, B, and EeH); 400 (C and D, I and J).
Dual Reconstituted Mice4.0 mg/mL; range, from 1.0 to 21.2 mg/mL). Fhb engraft-
ment was also conﬁrmed in eight animals by Western blot
analysis at week 10 (Figure 2B). By 18 weeks after surgery,
the hu-Alb levels declined, and only six animals had
detectable hu-Alb levels (Figure 2C). At the observational
end point, the presence of single CK-18þ or human cells
positive for apoptotic caspase-cleaved fragment of CK18
(M30) were sporadically found (not shown). The human
hematolymphoid tissue development was assessed by blood
FACS analysis for the percentage of human CD45þCD3þ
(T cells), CD19þ (B cells), and CD14þ (monocytes). All
animals successfully established a human immune system.
To improve the engraftment of Fhbs, we used the second
approach, in which two types of cells (106 cells/mouse freshly
isolated Fhbs and HSCs at 1:1 ratio) were co-transplanted by
intrasplenic infusion in treosulfan-conditioned mice. We ex-
pected that the dynamic interaction between HSCs and Fhbs
would support differentiation/maturation into hepatocytes.24
At week 10 after transplantation, the concentration of hu-Alb
in plasma was 10 times lower than with the ﬁrst approach
(median, 0.5 mg/mL; range, 0.1e1.9 mg/mL) (Figure 2D). We
assumed that the migration and the engraftment of Fhbs were
delayed. Fhbs did not sustain, as in scheme I, and were not
detected by immunohistological evaluation of liver tissue
samples. However, hematolymphoid reconstitution was suc-
cessful in all animals.
Finally, as an alternative third approach, the transplan-
tation of adult cryopreserved hepatocytes (2  106 cells/
mouse) was performed, followed by intravenous injection of
major histocompatibility complex mismatched cryopre-
served HSCs (0.5  106 cells/mouse) in eight animals
(Figures 2E and 3). The infusion of mature hepatocytes
ensured the stable engraftment and expansion of human cells
(Figures 2E and 3, A, B, and I). The median hu-Alb con-
centration in the peripheral blood 15 weeks after trans-
plantation was 43 mg/mL (range, 0.3e239 mg/mL) and
continued to increase up to 30 weeks of observation (median,
111.6 mg/mL; range, 6.6e312 mg/mL). The clusters of
CK18þ human hepatocytes were present at the end point of
observation, as seen on two representative mice liver tissue
slides (Figure 3, AeD). The areas occupied by human
CK18þ cells in selected sections were 4.8% to 6.8% of mouse
liver tissues. These results showed that adult hepatocytes
were able to survive and expand in uPA-NOG mice. Con-
ditioning with treosulfan did not have a negative effect on
hepatocyte engraftment. For all three experimental schemes,
the increase of the levels of liver damage determined by ALT
was similar; however, only the transplantation of mature
hepatocytes and HSCs in uPA-NOG mice appeared to be a
reliable way to create dual reconstituted mice.
Hemato-Lymphoid Reconstitution in uPA-NOG Mice
All animals conditioned with treosulfan and which received
a transplant with fetal liver-derived CD34þ HSCs success-
fully developed a human immune system. Human CD45þThe American Journal of Pathology - ajp.amjpathol.orgcells were detected in the peripheral blood 23 to 30 weeks
after HSC transplantation. The proportion of human CD45þ
cells for all three schemes was similar (median, approxi-
mately 50%e60%) to the lymphocyte gate (Figure 4,105
Figure 4 FACS analysis of blood from uPA-NOG
mice for human cell population. A: Representative
plots of six-color panel staining and analysis
strategy (50 mL of blood; mouse 1561). B: In all
experimental schemes of HSC transplantation, the
comparable amount of human CD45þ cells and
human CD4-to-CD8 cell ratios were found. Scheme I
was matched same fetal liverederived HSCs injec-
ted i.v.; Scheme II was same fetal liverederived
cells infused ispl.; and Scheme III was mismatched
fetal liverederived HSCs injected i.v. in mice that
received a transplant with adult hepatocytes. The
differences in the proportion of B (CD45þCD19þ)
and T (CD45þCD3þ) cells between the three ap-
proaches was related to the amount of transplanted
HSCs and the time of analysis. C and D: Comparison
of peripheral blood lymphoid reconstitution after
non-myeloablative conditioning with treosulfan of
uPA-NOG and NSG mice. The age and route of HSC
administration after treosulfan conditioning in
uPA-NOG mice did not affect the levels of recon-
stitution (C). Treosulfan conditioning and HSCs
derived from umbilical cord blood intravenous
transplantation in NSG mice resulted in comparable
reconstitution, as was previously observed with NSG
mice transplanted intrahepatically after irradiation
at birth25,26,31e33 (D). Individual values and me-
dians are shown. Cy5, cyanine 5; FITC, ﬂuorescein
isothiocyanate; FSC, forward scatter; PE, phycoer-
ythrin; SSC, side scatter.
Gutti et alAeD). Furthermore, the proportion of CD4 and CD8 pos-
itive T cells within the pool of CD3þ lymphocytes was also
similar for animals that received a transplant either i.v. or
ispl. with matched or mismatched hepatocytes. For scheme I
and II, the animals received a transplant with 106 CD34þ
HSCs, whereas the animals received a transplant with 0.5 106106 cells in scheme III. The difference in the amount of
transplanted HSCs can explain the different human B-cell
proportions in the peripheral blood. Such different dynamics
could also be donor dependent and is normally observed in
NSG/NOG or double knockout strains of mice.25e30 Treo-
sulfan conditioning was equally efﬁcient for the engraftmentajp.amjpathol.org - The American Journal of Pathology
Dual Reconstituted Miceof human CD34þ cells derived from fetal liver and umbil-
ical cord blood (Figure 4D). The level of immune recon-
stitution was comparable with engraftment achieved after
sublethal irradiation of newborn NSG mice.26,31e34
Liver Morphology in Dual Reconstituted uPA-NOG Mice
As was shown in the original description of the uPA-NOG
mice,15 the mild liver damage led to ﬁbrotic/cirrhotic changes
in these mice by 38 to 40 weeks of age. We analyzed the liver
tissue of six dual reconstituted mice among the eight animals
that received a transplant. Two animals died between 26 and
30 weeks after hepatocyte transplantation. We found that
hemato-lymphoid reconstitution was accompanied by the
repopulation of mouse liver with human immune cells. Portal
triads were inﬁltrated with human HLA-DRþ and CD68þ
cells. Subsequently, 11 mice had signiﬁcant parenchymal
inﬁltrates. This liver inﬁltration by human cells activated
macrophages/lymphocytes, which was reminiscent of
infection-induced myeloid cell aggregates.35 In addition to
portal stroma, these animals had an increase in the expression
of a-smooth muscle actin in the same areas (Figure 3, EeH).
Only three of the analyzed mice had a mild collagen depo-
sition (detected by trichrome staining) and human macro-
phages with digested fragments (not shown). We expected to
see cell-mediated rejection in animals reconstituted with adult
hepatocytes and mismatched HSCs; however, CD8þ cell
expansion or interaction with CK18þ cells was not evident.
The livers were populated with human HLA-DRþ macro-
phages/histiocytes (Figure 3, E and F), and small Kupffer
cells were found in the vascular sinuses (Figure 3J). Impor-
tantly, in some sham-operated mice and fetal cell-
reconstituted mice with higher levels of T-cell repopulation,
a signiﬁcant number of human CD4 and CD8 cells were also
present (not shown). In addition, splenic tissues contained
well-developed follicular structures composed of human
cells. We did not ﬁnd any CK-18þ cells in spleens. Five an-
imals had foci of human macrophage clusters and multinu-
cleated macrophages, which could be a sign of xenoreaction.
None of the animals developed signs of graft-versus-host
disease with hair loss, which is often observed in human-
ized mice that received a co-transplant with fetal thymus/
liver28 and rarely observed on NSG mice that received a
transplant with HSCs. Human macrophage inﬁltrates could
be related to the possible increase in the translocation of mi-
crobial products in highly immunodeﬁcient animals. Thus, in
mismatched co-transplantation of hepatocytes and HSCs, the
chances for the cellular immune-mediated rejection of hepa-
tocytes were low. However, human immune cell inﬁltration
associated with xenoreaction or the translocation of bacterial
products does exacerbate inherited liver pathology.
Discussion
The experimental approaches for studies of human-
speciﬁc co-infections associated with HIV-1 are extremelyThe American Journal of Pathology - ajp.amjpathol.orglimited.1,26 The most desired model is a humanized mouse
that carries human hematolymphoid tissue (host for HIV-1,
Epstein-Barr virus, human T-lymphotropic virus, cytomeg-
alovirus, etc, viral pathogens, and bacteria) and hepatocytes
(as the target cells for hepatitis viruses, malaria para-
sites).5,25,36 We introduced uPA-NOG mice, a new mouse
strain, for dual reconstitution. uPA-NOG mice are a
convenient host and are ready for dual reconstitution at 6
weeks of age. We conﬁrmed the original observation15 that
these animals (males), at 6 to 8 weeks of age, have elevated
ALT levels and the ability to engraft permanently adult
hepatocytes. The fetal liver is a unique source of two types
of cells for dual reconstituted mice. Isolated by standard
procedures, fetal HSCs are functional and, with different
speed and efﬁciency, form human hematolymphoid tissue in
uPA-NOG mice and in NSG or NOG mice.37 Unfortunately,
the practical application of fetal hepatocytes is highly
limited. The reported short-term engraftment success of fetal
hepatocytes differentiated in vitro38 or cells differentiated
from embryonic stem cells22 did not warrant the expansion
and survival of these cells in the adult mouse liver. As shown
in our study, we were successful in the initial engraftment, but
the expansion of Fhbs was not sustained despite the ongoing
damage of hepatocytes in uPA-NOG mice. Furthermore, co-
transplantation with HSCs did not improve engraftment.
Several reports showed signiﬁcant and sustained engraftment
of Fhbs by sorting for E-cadherin-positive cells in Fah/
Rag2/mice.39 In this strain of mice, liver progenitors, which
differentiate into mature human hepatocytes, were successfully
infected with HBV. Unfortunately, mice on a Fah/Rag2/
gc/ background, which potentially could be more appro-
priate for co-transplantation, were much more fragile, and a
signiﬁcant loss of animals occurredwith nonsurgical or surgical
manipulations.
We expected that the addition of human vector-delivered
hepatocyte growth factor would facilitate the expansion of
fetal cells.40 In an additional experiment, uPA-NOG mice
received a transplant with Fhbs along with the intramuscular
injection of adenoviral vector-expressing human hepatocyte
growth factor (1  1011 particles/mouse),41 and the
engraftment of the fetal liver cells was not improved. This
observation agrees with previously reported studies on other
strains of mice whereby Fhbs can be engrafted but at limited
quantities and for a limited time.14,42,43 The direct com-
parison of fetal versus adult human hepatocyte trans-
plantation on Alb-uPAþ/-Rag2/gc/ showed that adult
cells repopulate better than fetal cells in BALB/c back-
ground mice.21 Moreover, even though the engraftment
reached a relatively signiﬁcant proportion as shown by
Washburn et al,13 these fetal-derived hepatocytes were not
able to efﬁciently support the replication and secretion of
HCV.25 We cannot exclude that the isolation of mature
hepatocytes from fetal livers that express asialo glycoprotein
receptor 1 could be a feasible approach to use matched
HSCs.22 However, adult hepatocytes are preferred for
establishing a metabolic panel and innate immunity that107
Gutti et alallows replication of not only HBV but also HCV. In
addition, adult hepatocytes can be transplanted with high
efﬁciency and can be sustained for a long period of time.6
However, for the last scenario, there is no easily obtain-
able source of syngeneic HSCs. The ability to obtain two
types of cells from the same donor is currently limited to a
few centers with human tissue biorepositories. We trans-
planted mismatched hepatocytes and HSCs, which can be
used to evaluate the viral replication of HIV and HBV co-
infection in the case of low-hepatic repopulation, or HIV
and HCV co-infection with high levels of liver humaniza-
tion. However, situations with mismatched transplantation
of liver in cases of chronic HCV infection are not rare.
The successful engraftment of human HSCs was ex-
pected,9 but we demonstrated that this engraftment could be
performed safely at ages >8 to 10 weeks without total body
irradiation by using non-myeloablative conditioning with
treosulfan.16e20 In conclusion, uPA-NOG mice serve as the
promising tool for dual human liver and hematolymphoid
reconstruction, to examine HIV-1eassociated co-infections,
and to develop new treatment approaches.
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